Form 4: Teva Pharma CAO Sells 12,300 Shares

Teva Pharmaceutical Industries Ltd.'s Chief Accounting Officer, Amir Weiss, sold 12,300 ordinary shares for approximately $30.20 per share under a pre-arranged trading plan.

Summary

• Amir Weiss, Chief Accounting Officer of Teva Pharmaceutical Industries Ltd., sold 12,300 ordinary shares.
• The transaction occurred on December 16, 2025.
• The shares were sold at a weighted average price of $30.2036 per share, with prices ranging from $30.20 to $30.205.
• Following the sale, Amir Weiss directly beneficially owns 5,650 ordinary shares.
• The transaction was made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.

Sentiment

Score: 4

Explanation: A Chief Accounting Officer selling shares, even under a 10b5-1 plan, can be perceived negatively by some investors as it reduces insider ownership. However, the pre-arranged nature mitigates some of the negative sentiment.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-scheduled sale not necessarily based on new material non-public information.

Negatives

• An insider, the Chief Accounting Officer, sold a significant number of shares (12,300 shares).
• The sale reduces the insider's direct beneficial ownership to 5,650 shares.

Future Outlook

NA

Industry Context

This is an insider transaction report for a pharmaceutical company. Insider sales can sometimes be viewed with caution by investors, though sales under a 10b5-1 plan are often considered less indicative of a negative outlook than open market sales.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a reduction in insider confidence, though the 10b5-1 plan mitigates this concern.

Key Dates

Recommendation

While an insider sale by the Chief Accounting Officer could be a negative signal, the transaction was executed under a Rule 10b5-1 plan, suggesting it was pre-scheduled and not necessarily based on new material information. Without further context on the company's performance or other market factors, this single transaction alone does not warrant a strong buy or sell recommendation. Investors should monitor future insider activity and company fundamentals.

Keywords

Teva Pharmaceutical Industries, TEVA, Insider Trading, Form 4, Share Sale, Amir Weiss, Chief Accounting Officer, Rule 10b5-1